Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q1 2026 · 10-Q
Revenue$0.00$0.00— vs Q1 2025 Net Income-$500.00K-$500.00KN/M vs Q1 2025 EPS Diluted-$0.01-$0.01N/M vs Q1 2025 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
-$302,000
N/M
Operating Cash Flow-$617,000N/M ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end